Experience with Hydroxychloroquine and Azithromycin in the COVID-19 Pandemic: Implications for QT Interval Monitoring

Archana Ramireddy; Harpriya Chugh; Kyndaron Reinier; Joseph Ebinger; Eunice Park; Michael Thompson; Eugenio Cingolani; Susan Cheng; Eduardo Marban; Christine M. Albert; Sumeet S. Chugh

doi:10.1101/2020.04.22.20075671

ABSTRACT

Background Despite a paucity of clinical evidence, hydroxychloroquine and azithromycin are being administered widely to patients with verified or suspected COVID-19. Both drugs may increase risk of lethal arrhythmias associated with QT interval prolongation.

Methods We performed a case series of COVID-19 positive/suspected patients admitted between 2/1/2020 and 4/4/2020 who were treated with azithromycin, hydroxychloroquine or a combination. We evaluated baseline and post-medication QT interval (QTc, Bazett’s) using 12-lead ECGs. Critical QTc prolongation was defined as: a) maximum QTc ≥500 ms (if QRS <120 ms) or QTc ≥550 (if QRS ≥120 ms) and b) increased QTc of ≥60 ms. Tisdale score and Elixhauser comorbidity index were calculated.

Results Of 490 COVID-19 positive/suspected patients, 314 (64%) received either/both drugs, and 98 (73 COVID-19 positive, 25 suspected) met study criteria (age 62±17 yrs, 61% male). Azithromycin was prescribed in 28%, hydroxychloroquine in 10%, and both in 62%. Baseline mean QTc was 448±29 ms and increased to 459±36ms (p=0.005) with medications. Significant prolongation was observed only in men (18±43 ms vs -0.2±28 ms in women, p=0.02). 12% of patients reached critical QTc prolongation. In a multivariable logistic regression, age, sex, Tisdale score, Elixhauser score, and baseline QTc were not associated with critical QTc prolongation (p>0.14). Changes in QTc were highest with the combination compared to either drug, with many-fold greater prolongation with the combination vs. azithromycin alone (17±39 vs. 0.5±40 ms, p=0.07). No patients manifested torsades de pointes.

Conclusions Overall, 12% of patients manifested critical QTc interval prolongation, and traditional risk indices failed to flag these patients. With the drug combination, QTc prolongation was several-fold higher compared to azithromycin alone. The balance between uncertain benefit and potential risk when treating COVID-19 patients with these drugs should be carefully assessed prior to use.

INTRODUCTION

The ongoing COVID-19 pandemic is an unprecedented public health challenge at a global level.¹ As of April 9, 2020, ≥395,000 Americans have tested positive and over ≥12,700 of those patients² have succumbed to this illness. In the absence of a vaccine or any proven therapeutic agent, hydroxychloroquine (HCQ) and azithromycin (AZ), often used in combination, have emerged as a potential therapy based on extremely limited clinical evidence.³ These drugs are currently being prescribed in COVID-19 positive or suspected patients in growing numbers across the US and around the world.⁴

HCQ is an anti-malarial drug which has also been used to treat arthritis and systemic lupus erythematosus. AZ is a macrolide antibiotic used to treat a wide variety of bacterial infections. Both drugs prolong the QT interval by blocking the KCNH2-encoded hERG/Kv11.1 cardiac potassium channel, thereby increasing the risk of torsades des pointes.^5-7 In general, HCQ is reasonably well-tolerated and used chronically in arthritis and SLE patients without heart rhythm monitoring.⁸ In 2013, the FDA issued a black warning for AZ following multiple reported cases of QTc prolongation followed by torsades des pointes.⁹ Since the use of these drugs in COVID-19 patients is so recent and based largely on in vitro studies¹⁰ and anecdotal observations¹¹, community prescribing practices are as-yet unclear. More importantly, there is no information available regarding the extent of QTc prolongation with a combination of HCQ and AZ. From first principles, simultaneous block of the hERG/Kv11.1 cardiac potassium channel with both agents may cause critical QTc prolongation and an elevated risk of torsades des pointes. We therefore evaluated prescribing practices and monitored the QTc interval in COVID-19 positive or suspected patients who received these medications.

METHODS

Patient Population

This study was approved by the Cedars-Sinai Institutional Review Board. We identified all patients with confirmed COVID-19 infection as well as patients under investigation (PUI) admitted at Cedars-Sinai Medical Center in Los Angeles, California between 2/1/2020 and 4/4/2020 who received either AZ and/or HCQ as part of their medical treatment. A detailed, retrospective chart review was then performed via the electronic health record (Epic, Verona, WI) at our institution. Of the PUI and confirmed COVID-19 cases, we only included patients who had at least two 12-lead electrocardiograms (ECGs) performed in our MUSE system between 1/1/2020 and 4/5/2020. Patients with paced ventricular rhythms, atrial fibrillation, atrial flutter, supraventricular tachycardia, or ECGs otherwise unsuitable for accurate QT interval measurement were excluded.

Additionally, patients without ECGs performed on day 2 of medication administration or later were excluded (Figure 1). Our hospital policy states that daily ECGs should be performed in all patients who are started on the combination of AZ and HCQ just prior to and for the duration of therapy. If a patient has QTc ≥ 470 ms at baseline or reaches critical QTc prolongation (defined below in Outcomes), then continuous telemetry monitoring is recommended.

Figure 1.

Study Design. *COVID-19 positive patients and patients under investigation (PUI). AZ=Azithromycin, HCQ=Hydroxychloroquine.

Data Collection and Definitions

We compared obtained standard 12-lead ECG parameters, including the corrected QT interval (QTc, Bazett’s formula) from the baseline ECG closest to and prior to medication administration, to the longest QTc observed post-medication administration up to 24 hours after the last medication dose. Given variability in heart rates, QTc prolongation was also evaluated using the Fridericia formula for correction of the QT interval. QT measurements were independently reviewed and validated by a cardiologist to ensure accuracy of the automatic measurement and manually re-measured if needed. Patients were assigned into to one of 3 three groups depending on which medication they received – AZ, HCQ, or AZ + HCQ. Patient demographics, clinical history, labs, and medications were obtained from detailed chart review, including risk factors to calculate the Tisdale score¹² and the Elixhauser comorbidity index¹³ for each patient. The Tisdale score consists of age ≥ 68 yrs, female sex, use of loop diuretics, potassium level ≤ 3.5 mEq/L, baseline QTc ≥ 450 ms, acute MI, number of QT prolonging medications, sepsis, and heart failure and has been developed as a risk score for QTc interval prolongation. The Elixhauser comorbidity index incorporates 21 different variables, including obesity, diabetes, peripheral artery disease, chronic kidney disease, HIV, and cancer and is used to predict in-hospital mortality.

Outcome

Outcomes of interest were baseline QTc ≥470 ms¹⁴, and post-medication critical QTc prolongation defined as follows: a) maximum post-medication QTc ≥500 ms (if QRS <120 ms) or QTc ≥550 (if QRS ≥120 ms) and b) mean increase from baseline QTc to maximum post-medication QTc of ≥60 ms.^{14, 15}

Statistical Analysis

We evaluated the mean change from baseline QTc to longest QTc overall and by medication type using repeated measures analysis of variance. We also evaluated the frequency of critical ECG changes overall, by medication type, and by patient characteristics using chi-square analyses. Given the relatively low number of patients who received HCQ alone, the decision was made to only compare AZ to the combination of AZ + HCQ. We used multivariable logistic regression to evaluate whether age, sex, Tisdale score, Elixhauser score, and baseline QTc were associated with critical QTc prolongation.

RESULTS

A total of 490 patients were admitted to our medical center with a verified or suspected diagnosis of COVID-19 during the study time period, and 314 (64%) were treated with AZ, HCQ, or the combination. Of these, 192 patients had a 12-lead ECG performed during treatment, and a subgroup of 98 confirmed COVID infection or PUI (age 62±17 yrs, 61% male) met criteria for inclusion in the study (Table 1). Ninety-two of the excluded patients either had ECGs with indeterminate QT intervals (see Methods) or no ECG on at day 2 of medication administration or later, and two patients had extreme variation in heart rate, with near doubling of heart rate between baseline and maximal QTc prolongation. Given the limitations of QT interval correction at significantly elevated heart rates, we excluded both patients from the final analysis. Only 1 patient included in the analysis required manual QT measurement using the MUSE electronic calipers and the tangent method of calculation. Of the 98 patients, 73 patients were COVID-19 positive, and 25 were PUI. AZ was prescribed in 28%, HCQ in 10%, and the combination in 62%.

View this table:

Table 1. Patient Characteristics

At baseline, the mean QTc was 448±29ms, and 20% of patients had QTc >470ms (Table 2). With drug administration, overall QTc increased to 459±36ms (p=0.005). A similar increase in QTc was observed using correction of the QT interval with the Fridericia formula (420±32 ms to 438±36, p<0.0001). Subgroup analysis by sex revealed baseline and post-drug QTc of 449.1±31.4ms and 467.3±37.8ms in men (p=0.002). In women, baseline and post-drug QTc were 444.9±24.1ms and 444.7±28.6ms (p=0.97). Significant prolongation was observed only in men versus women (18±43 ms vs -0.2±28 ms, p=0.02). Further analysis by sex showed no significant difference in Tisdale score or Elixhauser comorbidity index. High Tisdale scores were similar in men and women (62% vs 63%, p=0.88). The average Elixhauser comorbidity index in men was lower and non-significant when compared with women. A trend towards significance was noted when comparing overall BMI in men vs women – 42.4% of men were obese vs 26.3% of women (p=0.11).

View this table:

Table 2. ECG Characteristics

Of note, multiple patterns were observed for use, duration, and dosage of both medications. Though a majority (81.6%) of patients received at least a 5-day course of each medication, there were many patients who received a higher dose on day 1 compared to the dosage on days 2-5. For example, AZ was either given as PO or IV, and the dosage was either 500mg daily or 500mg on day 1 followed by 250mg daily on days 2-5. For HCQ, most patients (87.0%) received 400mg PO twice daily prior to receiving a dosage of 200mg PO twice daily on days 2-5. It was noted that the medications were either started together (50.8%), staggered by one day (29.5%), or administered more than one day after the other (19.7%). Patients with lower values of QTc at baseline were more likely to be started on the combination of the two medications. In contrast, patients with a higher baseline QTc were more likely to receive either HCQ or AZ rather than the combination.

The mean change in QTc values was greatest in the combined HCQ and AZ group, and when compared to the AZ group, QTc prolongation due to the combination was observed to be several-fold higher than due to AZ alone (17.2±39.0 ms vs 0.5±40.3 ms, p=0.07) (Figure 2). A subgroup of 12% of patients were observed to reach a critical level of QTc prolongation – either QTc ≥ 500ms (if QRS < 120ms), QTc ≥ 550ms (if QRS ≥ 120ms), or change in QTc ≥ 60ms (Figure 3). Among the 12 patients with critical QTc prolongation, 5 patients were on AZ, and 7 patients were on the combination of HCQ and AZ (Table 3).There were no significant differences in regards to age, sex, sepsis, diabetes, baseline QTc ≥450 ms, or number of QT prolonging medications. Patients with critical QTc prolongation had significantly greater use of loop diuretics (p=0.007) and acute MI (p=0.01) (Table 4). 75% of patients with critical QTc prolongation had a high Tisdale score whereas 60.5% of patients without critical QTc changes had a high Tisdale score (p=0.33). Similarly, there was no significant difference in the Elixhauser comorbidity indices of the two groups (p=0.86). In a multivariable logistic regression, none of the following predictors were significantly associated with critical QTc prolongation: age, sex, Tisdale score, Elixhauser score, and baseline QTc (p>0.14). No patients had syncope, torsades de pointes, or other lethal arrhythmias during or after drug administration.

View this table:

Table 3. Baseline and Post-Drug ECG Characteristics by Medication Administered

View this table:

Table 4. Characteristics of Patients with Critical QTc Prolongation

Figure 2.

Boxplot of QTc changes by medication group. The QTc change is greatest in the combined HCQ and AZ group, and when compared to the Azithromycin group alone, the change in QTc is borderline significant (p=0.07). AZ=Azithromycin, HCQ=Hydroxychloroquine.

Figure 3.

Change in QTc from baseline to post-medication administration. Critical QTc prolongation (Δ ≥60ms or QTc ≥500ms (≥550ms in pts with QRS≥120ms)) was observed in 12% of patients.

DISCUSSION

At a single large community medical center, we studied 98 COVID-19 positive or suspected patients with HCQ and AZ, administered either individually or in combination. Although lethal arrhythmias were not observed during the limited period of observation, 12% of patients attained critical QTc prolongation, and that QTc prolongation was many-fold higher when HCQ and AZ were administered in combination compared with AZ alone. Moreover, patients who achieved critical QTc prolongation were not distinguished by significantly higher Tisdale scores, nor by higher Elixhauser comorbidity indices.

Our finding of greatest QTc prolongation in the combined HCQ + AZ group is important. In our study, patients with lower values of QTc at baseline were more likely to be started on the combination of the two medications. In contrast, patients with a higher baseline QTc were more likely to receive either HCQ or AZ rather than the combination. This suggests that prescription practice may have been driven by a concern regarding excessive QTc prolongation with the use of both medications in combination. Further review of our data showed that some practitioners decided on a staggered dosing regimen of one drug followed by the other drug later in the hospital stay. However, given the prolonged half-lives of these medications, such practice still results in a combined drug effect on the QTc.

Another interesting finding in our study was that men had significantly higher rates of QTc prolongation than women. The incidence of torsade de pointes is known to be higher in women, and female sex is a risk factor in the Tisdale score for QT prolongation. The reasons for this discrepancy still need to be explained, but could be related to the majority of patients in our population being men. Since rates of high Tisdale scores and the Elixhauser comorbidity index were also not significantly varied between the sexes, this finding cannot be explained by differences in overall morbidity burden and would benefit from further study.

Overall, our findings support the need to monitor the QTc during the period that these two medications are administered, especially when used in combination. We were not able to distinguish patients more likely to have critical QTc prolongation by the Tisdale score or Elixhauser index, making monitoring during medication administration likely to be a safer approach. ¹⁴ In addition to QTc prolongation as a result of KCNH2-encoded hERG/Kv11.1 cardiac potassium channel blockage, both drugs can provoke potentially lethal arrhythmias by additional mechanisms.^{16, 17} In fact, polymorphic ventricular tachycardia with AZ has been reported in the absence of QTc prolongation.¹⁸ Given that critical QTc prolongation was observed with both administration of AZ (n=5) as well as the combination of HCQ + AZ (n=7), monitoring of the QTc interval should not be restricted to the combination of these drugs alone. This is consistent with the 2013 black box warning issued by the FDA regarding the increased risk of torsades de pointes with AZ.

Limitations

The variation in dosing patterns and duration of treatment for each medication are important to note as this can potentially influence when the ECG with the longest QTc may be observed. Due to inconsistency in obtaining daily ECGs during medication administration, we believe that the 12% of patients who experienced critical QTc prolongation was likely an under-estimation. Furthermore, variability in heart rates, especially in the setting of sepsis, can affect QT interval correction. We reported the QTc using Bazett’s correction, which is consistent with the majority of the published literature as well as ECG recording machines in typical use. The relatively small sample size does not allow for assessment of torsades des pointes risk with these agents.

CONCLUSION

Prescribing practices for AZ and HCQ amid the COVID-19 pandemic were found to be diverse, but the majority of patients in our study received a combination of the two drugs. Among patients prescribed AZ, HCQ, or a combination of both, 12% of patients achieved a critical level of QTc interval prolongation. QTc values were highest with the combination of HCQ and AZ, with QTc prolongation many-fold higher in the combination group than with AZ alone. Especially if ongoing clinical trials indicate benefit from use of these medications, these findings could inform clinical therapeutics and ECG monitoring in COVID-19 patients.

SOURCES OF FUNDING

Cedars-Sinai internal funds to Dr. Chugh, Pauline and Harold Price Chair in Cardiac Electrophysiology.

DISCLOSURES

None.

REFERENCES

1.↵
Park M, Cook AR, Lim JT, Sun Y and Dickens BL. A Systematic Review of COVID-19 Epidemiology Based on Current Evidence. J Clin Med. 2020;9;967. Available from:http://dx.doi.org/10.3390/jcm9040967.
OpenUrl Google Scholar
2.↵
WHO Health Emergency Coronavirus 19 Dashboard. 2020.
Google Scholar
3.↵
Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Dupont HT, Honore S, Colson P, Chabriere E, La Scola B, Rolain JM, Brouqui P and Raoult D. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020:105949.
Google Scholar
4.↵
Ohe M, Shida H, Jodo S, Kusunoki Y, Seki M, Furuya K and Goudarzi H. Macrolide treatment for COVID-19: Will this be the way forward? Biosci Trends. 2020. Available from: https://doi.org/10.5582/bst.2020.03058.
Google Scholar
5.↵
Hancox JC, Hasnain M, Vieweg WV, Crouse EL and Baranchuk A. Azithromycin, cardiovascular risks, QTc interval prolongation, torsade de pointes, and regulatory issues: A narrative review based on the study of case reports. Ther Adv Infect Dis. 2013;1:155-65.
OpenUrl CrossRef PubMed Google Scholar
6.
McGhie TK, Harvey P, Su J, Anderson N, Tomlinson G and Touma Z. Electrocardiogram abnormalities related to anti-malarials in systemic lupus erythematosus. Clin Exp Rheumatol. 2018;36:545-551.
OpenUrl Google Scholar
7.↵
Traebert M, Dumotier B, Meister L, Hoffmann P, Dominguez-Estevez M and Suter W. Inhibition of hERG K+ currents by antimalarial drugs in stably transfected HEK293 cells. Eur J Pharmacol. 2004;484:41-8.
OpenUrl CrossRef PubMed Web of Science Google Scholar
8.↵
Tang C, Godfrey T, Stawell R and Nikpour M. Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects. Intern Med J. 2012;42:968-78.
OpenUrl CrossRef PubMed Google Scholar
9.↵
Ray WA, Murray KT, Hall K, Arbogast PG and Stein CM. Azithromycin and the Risk of Cardiovascular Death. The New England Journal of Medicine. 2012;366:1881-1890.
OpenUrl CrossRef PubMed Web of Science Google Scholar
10.↵
Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, Liu X, Zhao L, Dong E, Song C, Zhan S, Lu R, Li H, Tan W and Liu D. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020. Available from: https://doi.org/10.1093/cid/ciaa237.
Google Scholar
11.↵
Lakkireddy DR, Chung MK, Gopinathannair R, Patton KK, Gluckman TJ, Turagam M, Cheung J, Patel P, Sotomonte J, Lampert R, Han JK, Rajagopalan B, Eckhardt L, Joglar J, Sandau K, Olshansky B, Wan E, Noseworthy PA, Leal M, Kaufman E, Gutierrez A, Marine JM, Wang PJ and Russo AM. Guidance for Cardiac Electrophysiology During the Coronavirus (COVID-19) Pandemic from the Heart Rhythm Society COVID-19 Task Force; Electrophysiology Section of the American College of Cardiology; and the Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology, American Heart Association. Heart Rhythm. 2020. Available from: https://doi.org/10.1161/CIRCULATIONAHA.120.047063.
Google Scholar
12.↵
Tisdale JE, Jaynes HA, Kingery JR, Mourad NA, Trujillo TN, Overholser BR and Kovacs RJ. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2013;6:479-87.
OpenUrl Abstract/FREE Full Text Google Scholar
13.↵
van Walraven C, Austin PC, Jennings A, Quan H and Forster AJ. A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data. Medical Care. 2009;47:626-633.
OpenUrl CrossRef PubMed Google Scholar
14.↵
Giudicessi JR, Noseworthy PA, Friedman PA and Ackerman MJ. Urgent guidance for navigating and circumventing the QTc prolonging and torsadogenic potential of possible pharmacotherapies for COVID-19. Mayo Clinic Proceedings. 2020;95.
Google Scholar
15.↵
Roden DM, Harrington RA, Poppas A and Russo AM. Considerations for Drug Interactions on QTc in Exploratory COVID-19 (Coronavirus Disease 2019) Treatment. Circulation. 2020. Available from: https://doi.org/10.1161/CIRCULATIONAHA.120.047521.
Google Scholar
16.↵
Capel RA, Herring N, Kalla M, Yavari A, Mirams GR, Douglas G, Bub G, Channon K, Paterson DJ, Terrar DA and Burton RA. Hydroxychloroquine reduces heart rate by modulating the hyperpolarization-activated current If: Novel electrophysiological insights and therapeutic potential. Heart Rhythm. 2015;12:2186-94.
OpenUrl PubMed Google Scholar
17.↵
Zhang M, Xie M, Li S, Gao Y, Xue S, Huang H, Chen K, Liu F and Chen L. Electrophysiologic Studies on the Risks and Potential Mechanism Underlying the Proarrhythmic Nature of Azithromycin. Cardiovasc Toxicol. 2017;17:434-440.
OpenUrl Google Scholar
18.↵
Kim MH, Berkowitz C and Trohman RG. Polymorphic ventricular tachycardia with a normal QT interval following azithromycin. Pacing Clin Electrophysiol. 2005;28:1221-2.
OpenUrl CrossRef PubMed Google Scholar

Posted April 25, 2020.

Download PDF

Author Declarations

Data/Code

Citation Tools

Get QR code

Tweet Widget

Subject Area

Cardiovascular Medicine

Reviews and Context

Comment

TRIP Peer Reviews

Community Reviews

Automated Services

Blogs/Media

Author Videos

Subject Areas

All Articles

Addiction Medicine (417)
Allergy and Immunology (739)
Anesthesia (216)
Cardiovascular Medicine (3168)
Dentistry and Oral Medicine (354)
Dermatology (268)
Emergency Medicine (469)
Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1125)
Epidemiology (13137)
Forensic Medicine (17)
Gastroenterology (878)
Genetic and Genomic Medicine (4963)
Geriatric Medicine (457)
Health Economics (761)
Health Informatics (3125)
Health Policy (1114)
Health Systems and Quality Improvement (1154)
Hematology (417)
HIV/AIDS (986)
Infectious Diseases (except HIV/AIDS) (14437)
Intensive Care and Critical Care Medicine (894)
Medical Education (462)
Medical Ethics (121)
Nephrology (511)
Neurology (4716)
Nursing (250)
Nutrition (699)
Obstetrics and Gynecology (856)
Occupational and Environmental Health (772)
Oncology (2431)
Ophthalmology (691)
Orthopedics (272)
Otolaryngology (335)
Pain Medicine (314)
Palliative Medicine (88)
Pathology (523)
Pediatrics (1263)
Pharmacology and Therapeutics (535)
Primary Care Research (535)
Psychiatry and Clinical Psychology (4054)
Public and Global Health (7281)
Radiology and Imaging (1630)
Rehabilitation Medicine and Physical Therapy (972)
Respiratory Medicine (952)
Rheumatology (468)
Sexual and Reproductive Health (485)
Sports Medicine (409)
Surgery (527)
Toxicology (66)
Transplantation (225)
Urology (195)

Comments

medRxiv aims to provide a venue for anyone to comment on a medRxiv preprint. Comments are moderated for offensive or irrelevant content (this can take ~24 h). Please avoid duplicate submissions and read our Comment Policy before commenting. The content of a comment is not endorsed by medRxiv.

medRxiv aims to inform readers about online discussion of this preprint occurring elsewhere. The content at the links below is not endorsed by either medRxiv or the preprint's authors.

Community reviews for this article:

There are no community reviews for this paper.

Automated Evaluations

Certain services provide automated analysis of preprints. Analyses invited by the authors are displayed at the top of this tab. Those done independently of authors are shown underneath . None of these analyses is endorsed by medRxiv.

Automated Evaluations:

There are no automated evaluations for this paper.

[1] 1.↵
Park M, Cook AR, Lim JT, Sun Y and Dickens BL. A Systematic Review of COVID-19 Epidemiology Based on Current Evidence. J Clin Med. 2020;9;967. Available from:http://dx.doi.org/10.3390/jcm9040967.
OpenUrl Google Scholar

[2] 2.↵
WHO Health Emergency Coronavirus 19 Dashboard. 2020.
Google Scholar

[3] 3.↵
Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Dupont HT, Honore S, Colson P, Chabriere E, La Scola B, Rolain JM, Brouqui P and Raoult D. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020:105949.
Google Scholar

[4] 4.↵
Ohe M, Shida H, Jodo S, Kusunoki Y, Seki M, Furuya K and Goudarzi H. Macrolide treatment for COVID-19: Will this be the way forward? Biosci Trends. 2020. Available from: https://doi.org/10.5582/bst.2020.03058.
Google Scholar

[5] 5.↵
Hancox JC, Hasnain M, Vieweg WV, Crouse EL and Baranchuk A. Azithromycin, cardiovascular risks, QTc interval prolongation, torsade de pointes, and regulatory issues: A narrative review based on the study of case reports. Ther Adv Infect Dis. 2013;1:155-65.
OpenUrl CrossRef PubMed Google Scholar

[6] 6.
McGhie TK, Harvey P, Su J, Anderson N, Tomlinson G and Touma Z. Electrocardiogram abnormalities related to anti-malarials in systemic lupus erythematosus. Clin Exp Rheumatol. 2018;36:545-551.
OpenUrl Google Scholar

[7] 7.↵
Traebert M, Dumotier B, Meister L, Hoffmann P, Dominguez-Estevez M and Suter W. Inhibition of hERG K+ currents by antimalarial drugs in stably transfected HEK293 cells. Eur J Pharmacol. 2004;484:41-8.
OpenUrl CrossRef PubMed Web of Science Google Scholar

[8] 8.↵
Tang C, Godfrey T, Stawell R and Nikpour M. Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects. Intern Med J. 2012;42:968-78.
OpenUrl CrossRef PubMed Google Scholar

[9] 9.↵
Ray WA, Murray KT, Hall K, Arbogast PG and Stein CM. Azithromycin and the Risk of Cardiovascular Death. The New England Journal of Medicine. 2012;366:1881-1890.
OpenUrl CrossRef PubMed Web of Science Google Scholar

[10] 10.↵
Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, Liu X, Zhao L, Dong E, Song C, Zhan S, Lu R, Li H, Tan W and Liu D. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020. Available from: https://doi.org/10.1093/cid/ciaa237.
Google Scholar

[11] 11.↵
Lakkireddy DR, Chung MK, Gopinathannair R, Patton KK, Gluckman TJ, Turagam M, Cheung J, Patel P, Sotomonte J, Lampert R, Han JK, Rajagopalan B, Eckhardt L, Joglar J, Sandau K, Olshansky B, Wan E, Noseworthy PA, Leal M, Kaufman E, Gutierrez A, Marine JM, Wang PJ and Russo AM. Guidance for Cardiac Electrophysiology During the Coronavirus (COVID-19) Pandemic from the Heart Rhythm Society COVID-19 Task Force; Electrophysiology Section of the American College of Cardiology; and the Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology, American Heart Association. Heart Rhythm. 2020. Available from: https://doi.org/10.1161/CIRCULATIONAHA.120.047063.
Google Scholar

[12] 12.↵
Tisdale JE, Jaynes HA, Kingery JR, Mourad NA, Trujillo TN, Overholser BR and Kovacs RJ. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2013;6:479-87.
OpenUrl Abstract/FREE Full Text Google Scholar

[13] 13.↵
van Walraven C, Austin PC, Jennings A, Quan H and Forster AJ. A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data. Medical Care. 2009;47:626-633.
OpenUrl CrossRef PubMed Google Scholar

[14] 14.↵
Giudicessi JR, Noseworthy PA, Friedman PA and Ackerman MJ. Urgent guidance for navigating and circumventing the QTc prolonging and torsadogenic potential of possible pharmacotherapies for COVID-19. Mayo Clinic Proceedings. 2020;95.
Google Scholar

[15] 15.↵
Roden DM, Harrington RA, Poppas A and Russo AM. Considerations for Drug Interactions on QTc in Exploratory COVID-19 (Coronavirus Disease 2019) Treatment. Circulation. 2020. Available from: https://doi.org/10.1161/CIRCULATIONAHA.120.047521.
Google Scholar

[16] 16.↵
Capel RA, Herring N, Kalla M, Yavari A, Mirams GR, Douglas G, Bub G, Channon K, Paterson DJ, Terrar DA and Burton RA. Hydroxychloroquine reduces heart rate by modulating the hyperpolarization-activated current If: Novel electrophysiological insights and therapeutic potential. Heart Rhythm. 2015;12:2186-94.
OpenUrl PubMed Google Scholar

[17] 17.↵
Zhang M, Xie M, Li S, Gao Y, Xue S, Huang H, Chen K, Liu F and Chen L. Electrophysiologic Studies on the Risks and Potential Mechanism Underlying the Proarrhythmic Nature of Azithromycin. Cardiovasc Toxicol. 2017;17:434-440.
OpenUrl Google Scholar

[18] 18.↵
Kim MH, Berkowitz C and Trohman RG. Polymorphic ventricular tachycardia with a normal QT interval following azithromycin. Pacing Clin Electrophysiol. 2005;28:1221-2.
OpenUrl CrossRef PubMed Google Scholar

Experience with Hydroxychloroquine and Azithromycin in the COVID-19 Pandemic: Implications for QT Interval Monitoring

ABSTRACT

INTRODUCTION